Sandoz Capital Markets Day
June 2023
Sandoz hosted two Capital Markets Days (CMDs), on June 8 and June 12, at the New York stock exchange and the London stock exchange. The goal of both events was to outline its strong heritage, reshaped growth strategy and plans for sustainable market leadership, following the proposed 100% spin-off from Novartis in the second half of this year.
Click here to view key materials including the press release and CMD deck, as well as to listen to the recordings.
What We Do
At Sandoz our work is focused on improving access to medicines, access to medical information and access to medical capacity building.
Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from us.
Job Search
A once-in-a-career opportunity to become a founder of a new Sandoz! Join Us!
Sandoz investing to increase production of much-needed antibiotics
Sandoz is pushing ahead with its capacity expansion program for much-needed antibiotic medicines. As shown in the photo, construction of a new USD 50m plant, announced in November 2022, is already well underway. Our Kundl site in Austria will also manufacture antibiotics for children (pediatric formulations). In total, the company is investing USD 250m to expand its antibiotic manufacturing capabilities in Europe. This has already led to a double-digit increase in capacity in 2022 and another double-digit increase is planned for 2023.
Latest News
Sandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off[1],[2]
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Products & Services
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.
Biopharmaceuticals
We are a pioneer and a global leader in biosimilars with over a decade of experience.